Abstract
Introduction
This study aimed at evaluating the efficacy of ultrasound for the early detection of breast cancers in BRCA1/2 mutation carriers.
Methods
Between 01/1997 and 10/2008 221 BRCA1/2 mutation carriers participated in a breast cancer screening program which included semi-annual ultrasound in combination with annual mammography and magnetic resonance imaging (MRI). Women underwent on average (median) five semi-annual screening rounds with a range of one to 22 appointments, totaling 1,855 rounds of screening. All three imaging modalities were coded according to the American College of Radiology (BI-RADS classification).
Results
In total, we detected 27 BRCA-associated breast cancers in 25 patients. The sensitivity was 77 % for ultrasound, 27 % for mammography, and 100 % for MRI. Three tumors were detected directly as a result of only the semi-annual ultrasound screen.
Conclusions
Due to the specific tumor morphology and the considerably elevated tumor doubling time, mutation carriers benefit from the addition of semi-annual ultrasound screening as a sensitive and cost-effective method.
Similar content being viewed by others
Abbreviations
- CBE:
-
Clinical breast examination
- US:
-
Ultrasound
- MG:
-
Mammography
- MRI:
-
Magnetic resonance imaging
- ACR:
-
American College of Radiology
- BI-RADS:
-
Breast Imaging and Reporting and Data System
References
Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997; 349: 1505–10
Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689
Tilanus-Linthorst MM, Kriege M, Boetes C et al (2005) Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 41:1610–1617
Da Silva L, Lakhani SR (2010) Pathology of hereditary breast cancer. Mod Pathol 23:S46–S51
Rhiem K, Flucke U, Schmutzler RK (2006) BRCA1-associated breast carcinomas frequently present with benign sonographic features. Am J Roentgenol 186:E11–E12 author reply E12-3
Brekelmans CT, Seynaeve C, Bartels CC et al (2001) Rotterdam Committee for Medical and Genetic Counseling: effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19:924–930
Vasen HFA, Tesfay E, Boonstra H et al (2005) Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 41:549–554
Komenaka IK, Ditkoff BA, Joseph KA et al (2004) The development of interval breast malignancies in patients with BRCA mutations. Cancer 100:2079–2083
Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325
Tilanus-Linthorst MM, Obdeijn IM, Hop WC et al (2007) BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Can Res 13(24):7357–7362
Gierach GL, Loud JT, Chow CK, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Vachon C, Gail MH, Greene MH (2010) Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. Breast Cancer Res Treat 123(1):245–255
Lehman C, Lee C, Loving V, Portillo M, Peacock S, DeMartini W (2012) Accuracy and value of breast ultrasound for primary imaging evaluation of symptomatic women 30-39 years of age. AJR 199:1169–1177
Meindl A (2002) Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97:472–480
Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Wagner T, Simard J, Evans G, Peock S, Fricker JP, Nogues C, Van’t Veer L, Van Leeuwen FE, Goldgar DE (2006) Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol 24(21):3361–3366
American College of Radiology and (ACR) reporting system (1993) Breast Imaging and Reporting and Data System (BI-RADS), 2nd edn. American College of Radiology, Reston, pp 15–18
Mesurolle B, Kadoch L, El-Khoury M, Lisbona A, Dendukuri N, Foulkes WD (2007) Sonographic features of breast carcinoma presenting as masses in BRCA gene mutation carriers. J Ultrasound Med 26(6):817–824
Berg WA (2009) Tailored supplemental screening for breast cancer: what now and what next? AJR 193:1188 author reply
Hwang ES, McLennan JL, Moore DH et al (2007) Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 25(6):642–647
Warner W, Causer Petrina A, Wong John W-N et al (2011) Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study. Breast J 17(1):9–17
Kuhl CK, Schmutzler RK, Leutner CC et al (2000) Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215:267–279
Libermann L (2004) Breast cancer sreening with MRI—What are the data for the patients at high risk? N Eng J Med 351:497–500 Editorial
Kriege M, Brekelmans CT, Boetes C et al (2004) Magnetic Resonance Imaging Screening Study Group: efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437
Leach MO, Boggis CR, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365:1769–1778
Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 107:24–30
Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ (2012) Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 21(9):1458–1468
Saslow D, Boetes C, Burke W et al (2007) American Cancer Society Breast Cancer Advisory Group: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89 Erratum in: CA Cancer J Clin 2007, 57:185
Dent R, Warner E (2007) Screening for hereditary breast cancer. Semin Oncol 34:392–400
NICE Guidelines: CG41: Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care
Acknowledgement
Our work has been supported by the German Cancer Aid.
Conflict of interest
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Additional information
Both K. Bosse and M. Graeser contributed equally to this work.
Rights and permissions
About this article
Cite this article
Bosse, K., Graeser, M., Goßmann, A. et al. Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 289, 663–670 (2014). https://doi.org/10.1007/s00404-013-3022-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-013-3022-6